It has been shown that deferiprone reduces the high expression of NF-κB and COX2 in cardiomyocytes of DCM rats by interfering with the inflammatory signaling pathway, thus alleviating the development of DCM(L et al., 2019; Li et al., 2020c; Cheng et al., 2021). This evidence concerns the gene NFKB1 and familial dilated cardiomyopathy.